Company news
Biovica International Ab Class B (OMXSTO:BIOVIC_B) news
Biovica International Ab Class B news releases on 6ix. Latest, Sep 16, 2026: Announcement from the Annual General Meeting in Biovica International AB
Press releases & updates
Announcement from the Annual General Meeting in Biovica International AB
September 16, 2026
Biovica Resolves on a Fully Guaranteed Rights Issue of SEK 29.2 Million
September 9, 2026
Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026
March 5, 2026
Biovica Signs Client Bill Agreement with Leading U.S. NCI-Designated Cancer Center
December 15, 2025
Biovica Carries Out a Directed Share Issue of Approximately MSEK 42.2
August 13, 2025
Biovica announces outcome of rights issue
August 5, 2025
Biovica Launches DiviTum(R) TKa for Use in Early Breast Cancer
July 25, 2025
Biovica Awarded 3 MSEK Contract - 4th from Leading Tier-1 Pharma Company
July 24, 2025
Biovica Granted New European Patent
June 26, 2025
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
June 11, 2025
Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress
June 10, 2025
Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
June 10, 2025
New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types
May 23, 2025
Biovica Signs Major Service Agreement and First Study Work Order of 4 MSEK
May 19, 2025
Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa
May 13, 2025